Cargando…

CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer

PURPOSE: The aim of this study was to investigate the degree of infiltration of CD8+ tumor-infiltrating lymphocytes (TILs) including high and low density in lung sarcomatoid carcinoma (LSC) and their clinicopathological significance. PATIENTS AND METHODS: The density of CD8+ TILs in paraffin-embedde...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiewei, He, Qingmei, Liu, Jun, Xiao, Yongbo, Xiao, Canhua, Chen, Keming, Xie, Dan, Zhang, Xinke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145683/
https://www.ncbi.nlm.nih.gov/pubmed/30271199
http://dx.doi.org/10.2147/CMAR.S169074
_version_ 1783356291588030464
author Chen, Jiewei
He, Qingmei
Liu, Jun
Xiao, Yongbo
Xiao, Canhua
Chen, Keming
Xie, Dan
Zhang, Xinke
author_facet Chen, Jiewei
He, Qingmei
Liu, Jun
Xiao, Yongbo
Xiao, Canhua
Chen, Keming
Xie, Dan
Zhang, Xinke
author_sort Chen, Jiewei
collection PubMed
description PURPOSE: The aim of this study was to investigate the degree of infiltration of CD8+ tumor-infiltrating lymphocytes (TILs) including high and low density in lung sarcomatoid carcinoma (LSC) and their clinicopathological significance. PATIENTS AND METHODS: The density of CD8+ TILs in paraffin-embedded tissue sections from 100 LSC patients was detected by immunohistochemical staining, and the relationship of CD8+ TILs with clinicopathological features and prognosis was analyzed. RESULTS: The chi-squared test showed that the degree of infiltration of CD8+ TILs was significantly correlated with the clinicopathological stage and T stage of LSC (P<0.05). The univariate analysis demonstrated that tumor size, clinicopathological stage, T stage, N stage, M stage, and CD8+ TILs are risk factors that affect prognosis of the patients (P<0.05). The mean overall survival (OS) of LSC patients with a high density of CD8+ TILs was 92.3 months, which was significantly higher than 31.2 months in patients with a low density of CD8+ TILs (P<0.05). Cox regression multivariate analysis confirmed that the density of CD8+ TILs was an independent prognostic factor for OS time of LSC patients (hazard ratio=0.455, P<0.05). CONCLUSION: CD8+ TILs could be used as an effective prognostic index for LSC patients, and a high density of CD8+ TILs in tumor tissue may predict a better outcome.
format Online
Article
Text
id pubmed-6145683
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61456832018-09-28 CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer Chen, Jiewei He, Qingmei Liu, Jun Xiao, Yongbo Xiao, Canhua Chen, Keming Xie, Dan Zhang, Xinke Cancer Manag Res Original Research PURPOSE: The aim of this study was to investigate the degree of infiltration of CD8+ tumor-infiltrating lymphocytes (TILs) including high and low density in lung sarcomatoid carcinoma (LSC) and their clinicopathological significance. PATIENTS AND METHODS: The density of CD8+ TILs in paraffin-embedded tissue sections from 100 LSC patients was detected by immunohistochemical staining, and the relationship of CD8+ TILs with clinicopathological features and prognosis was analyzed. RESULTS: The chi-squared test showed that the degree of infiltration of CD8+ TILs was significantly correlated with the clinicopathological stage and T stage of LSC (P<0.05). The univariate analysis demonstrated that tumor size, clinicopathological stage, T stage, N stage, M stage, and CD8+ TILs are risk factors that affect prognosis of the patients (P<0.05). The mean overall survival (OS) of LSC patients with a high density of CD8+ TILs was 92.3 months, which was significantly higher than 31.2 months in patients with a low density of CD8+ TILs (P<0.05). Cox regression multivariate analysis confirmed that the density of CD8+ TILs was an independent prognostic factor for OS time of LSC patients (hazard ratio=0.455, P<0.05). CONCLUSION: CD8+ TILs could be used as an effective prognostic index for LSC patients, and a high density of CD8+ TILs in tumor tissue may predict a better outcome. Dove Medical Press 2018-09-13 /pmc/articles/PMC6145683/ /pubmed/30271199 http://dx.doi.org/10.2147/CMAR.S169074 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Jiewei
He, Qingmei
Liu, Jun
Xiao, Yongbo
Xiao, Canhua
Chen, Keming
Xie, Dan
Zhang, Xinke
CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title_full CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title_fullStr CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title_full_unstemmed CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title_short CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
title_sort cd8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145683/
https://www.ncbi.nlm.nih.gov/pubmed/30271199
http://dx.doi.org/10.2147/CMAR.S169074
work_keys_str_mv AT chenjiewei cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT heqingmei cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT liujun cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT xiaoyongbo cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT xiaocanhua cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT chenkeming cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT xiedan cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer
AT zhangxinke cd8tumorinfiltratinglymphocytesasanovelprognosticbiomarkerinlungsarcomatoidcarcinomaararesubtypeoflungcancer